An update on inclisiran for the treatment of elevated LDL cholesterol

References

• Ray KK, Ference BA, Severin T, et al. World heart federation cholesterol roadmap 2022. Glob Heart. 2022;17(1):75. doi: 10.5334/gh.1154
   PubMed Web of Science ®Google Scholar
• Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020 Dec 22;76(25):2982–3021. doi: 10.1016/j.jacc.2020.11.010
   PubMed Web of Science ®Google Scholar
• Tokgozoglu L, Libby P. The dawn of a new era of targeted lipid-lowering therapies. Eur Heart J. 2022 Sep 7;43(34):3198–3208. doi: 10.1093/eurheartj/ehab841
   PubMed Web of Science ®Google Scholar
• Brandts J, Ray KK. Novel and future lipid-modulating therapies for the prevention of cardiovascular disease. Nat Rev Cardiol. 2023 Sep;20(9):600–616. doi: 10.1038/s41569-023-00860-8
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111–188. doi: 10.1093/eurheartj/ehz455
   PubMed Web of Science ®Google Scholar
• Ray KK, Haq I, Bilitou A, et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health Eur. 2023 Jun;29:100624. doi: 10.1016/j.lanepe.2023.100624
   PubMedGoogle Scholar
• Ray KK, Molemans B, Schoonen WM, et al. EU-Wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021 Sep 20;28(11):1279–1289. doi: 10.1093/eurjpc/zwaa047
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015 Jun 18;372(25):2387–2397. doi: 10.1056/NEJMoa1410489
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017 May 4;376(18):1713–1722. doi: 10.1056/NEJMoa1615664
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018 Nov 29;379(22):2097–2107. doi: 10.1056/NEJMoa1801174
   PubMed Web of Science ®Google Scholar
• Vallejo-Vaz AJ, Stevens CAT, Lyons ARM, et al. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS familial hypercholesterolaemia studies collaboration (FHSC). The Lancet. 2021 Nov 6;398(10312):1713–1725. doi: 10.1016/S0140-6736(21)01122-3.
   PubMed Web of Science ®Google Scholar
• Bytyci I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022 Sep 7;43(34):3213–3223. doi: 10.1093/eurheartj/ehac015
   PubMed Web of Science ®Google Scholar
• Schwartz JB, Schmader KE, Hanlon JT, et al. Pharmacotherapy in older adults with cardiovascular disease: report from an American college of cardiology, American geriatrics society, and national institute on aging workshop. J Am Geriatr Soc. 2019 Feb;67(2):371–380.
   PubMed Web of Science ®Google Scholar
• Khunti K, Danese MD, Kutikova L, et al. Association of a combined measure of adherence and treatment intensity with cardiovascular outcomes in patients with atherosclerosis or other cardiovascular risk factors treated with statins and/or ezetimibe. JAMA Netw Open. 2018 Dec 7;1(8):e185554. doi: 10.1001/jamanetworkopen.2018.5554
   PubMed Web of Science ®Google Scholar
• Rodriguez F, Maron DJ, Knowles JW, et al. Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2019 Mar 1;4(3):206–213. doi: 10.1001/jamacardio.2018.4936
   PubMed Web of Science ®Google Scholar
• Piazza G, Desai NR, Baber U, et al. Practical solutions for implementation of blood cholesterol guidelines in clinical practice. Trends Cardiovasc Med. 2023 Aug 25. doi: 10.1016/j.tcm.2023.08.001
   Google Scholar
• Katzmann JL, Packard CJ, Chapman MJ, et al. Targeting RNA with antisense oligonucleotides and small interfering RNA: JACC state-of-the-art review. J Am Coll Cardiol. 2020 Aug 4;76(5):563–579. doi: 10.1016/j.jacc.2020.05.070
   PubMed Web of Science ®Google Scholar
• Nishikido T. Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease. Cardiovasc Diabetol. 2023 Jan 30;22(1):20. doi: 10.1186/s12933-023-01752-4
   PubMed Web of Science ®Google Scholar
• Ebenezer O, Comoglio P, Wong GK, et al. Development of novel siRNA therapeutics: a review with a focus on Inclisiran for the Treatment of Hypercholesterolemia. Int J Mol Sci. 2023 Feb 16;24(4):4019. doi: 10.3390/ijms24044019
   PubMed Web of Science ®Google Scholar
• Seidah NG, Prat A. The multifaceted biology of PCSK9. Endocr Rev. 2022 May 12;43(3):558–582. doi: 10.1210/endrev/bnab035
   PubMed Web of Science ®Google Scholar
• Ferri N, Corsini A, Ruscica M. Hypocholesterolaemic treatment in coronary unit: from statins to anti PCSK9 therapies and bempedoic acid. Eur Heart J Suppl. 2023 Apr;25(Suppl B):B55–B59. doi: 10.1093/eurheartjsupp/suad068
   PubMedGoogle Scholar
• Summary product characteristics of Repatha [cited 2023 Mar 16]. Available from: https://www.ema.europa.eu/en/documents/product-information/repatha-epar-product-information_en.pdf.on
   Google Scholar
• Summary product characteristics of Praluent [cited 2023 Mar 16]. Available from: https://www.ema.europa.eu/en/documents/product-information/praluent-epar-product-information_en.pdf.on
   Google Scholar
• Summary product characteristics of Leqvio [cited 2023 Mar 16]. Available from: https://www.ema.europa.eu/en/documents/product-information/leqvio-epar-product-information_en.pdf.on
   Google Scholar
• Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017 Apr 13;376(15):1430–1440. doi: 10.1056/NEJMoa1615758
   PubMed Web of Science ®Google Scholar
• Brandts J, Ray KK. Low density lipoprotein cholesterol-lowering strategies and population health: time to move to a cumulative exposure model. Circulation. 2020 Mar 17;141(11):873–876. doi: 10.1161/CIRCULATIONAHA.119.043406
   PubMed Web of Science ®Google Scholar
• Kasichayanula S, Grover A, Emery MG, et al. Clinical pharmacokinetics and pharmacodynamics of Evolocumab, a PCSK9 inhibitor. Clin Pharmacokinet. 2018 Jul;57(7):769–779.
   PubMed Web of Science ®Google Scholar
• Manniello M, Pisano M. Alirocumab (praluent): first in the new class of PCSK9 inhibitors. P T. 2016 Jan;41(1):28–53.
   PubMedGoogle Scholar
• Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017 Jan 5;376(1):41–51. doi: 10.1056/NEJMoa1609243
   PubMed Web of Science ®Google Scholar
• Kallend D, Stoekenbroek R, He Y, et al. Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment. J Clin Lipidol. 2022 Mar;16(2):208–219. doi: 10.1016/j.jacl.2022.01.001
   PubMed Web of Science ®Google Scholar
• Wright RS, Collins MG, Stoekenbroek RM, et al. Effects of renal impairment on the pharmacokinetics, efficacy, and safety of Inclisiran: an analysis of the ORION-7 and ORION-1 studies. Mayo Clin Proc. 2020 Jan;95(1):77–89.
   PubMed Web of Science ®Google Scholar
• Kallend D, Mason J, Smith PF, et al. An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers: a phase I, randomized study. Clin Transl Sci. 2022 Nov;15(11):2663–2672.
   PubMed Web of Science ®Google Scholar
• Ray KK, Troquay RPT, Visseren FLJ, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 2023 Feb;11(2):109–119.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020 Apr 16;382(16):1520–1530. doi: 10.1056/NEJMoa1913805
   PubMed Web of Science ®Google Scholar
• Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020 Apr 16;382(16):1507–1519. doi: 10.1056/NEJMoa1912387
   PubMed Web of Science ®Google Scholar
• Wright RS, Ray KK, Raal FJ, et al. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J Am Coll Cardiol. 2021 Mar 9;77(9):1182–1193. doi: 10.1016/j.jacc.2020.12.058
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.Gov. Trial to assess the effect of long term dosing of inclisiran in subjects with high CV risk and elevated LDL-C (ORION-8) (NCT03814187) [cited 2023 Jul 14]. Available from: https://www.clinicaltrials.gov/study/NCT03814.
   Google Scholar
• Wright R, Raal F, Koenig W, et al. ORION-8: long-term efficacy and safety of twice-yearly inclisiran in high cardiovascular risk patients. Oral Presentation presented at ESC Congress 2023 on 28 August 2023 [cited 2023 Jan 5]. Available from: https://esc365.escardio.org/presentation/272197?query=ORION-8.
   Google Scholar
• Landmesser U, Koenig W, Leiter LA, et al. Inclisiran in patients with prior myocardial infarction: a post hoc pooled analysis of the ORION-10 and ORION-11 phase 3 randomised trials. Atherosclerosis. 2023 Dec;386:117354. doi: 10.1016/j.atherosclerosis.2023.117354
   PubMed Web of Science ®Google Scholar
• Koenig W, Ray KK, Landmesser U, et al. Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11. Am J Prev Cardiol. 2023 Jun;14:100503. doi: 10.1016/j.ajpc.2023.100503
   PubMedGoogle Scholar
• Koenig W, Conde LG, Landmesser U, et al. Efficacy and safety of inclisiran in patients with polyvascular disease: pooled, post hoc analysis of the ORION-9, ORION-10, and ORION-11 phase 3 randomized controlled trials. Cardiovasc Drugs Ther. 2022 Dec 23. doi: 10.1007/s10557-022-07413-0
   Web of Science ®Google Scholar
• Ray KK, Kallend D, Leiter LA, et al. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J. 2022 Dec 21;43(48):5047–5057. doi: 10.1093/eurheartj/ehac615
   PubMed Web of Science ®Google Scholar
• Padam P, Barton L, Wilson S, et al. Lipid lowering with inclisiran: a real-world single-centre experience. Open Heart. 2022 Dec;9(2):e002184.
   PubMed Web of Science ®Google Scholar
• Mulder J, Galema-Boers AMH, Roeters van Lennep JE. First clinical experiences with inclisiran in a real-world setting. J Clin Lipidol. 2023 Nov;17(6):818–827. doi: 10.1016/j.jacl.2023.09.005
   PubMed Web of Science ®Google Scholar
• Makhmudova U, Schatz U, Perakakis N, et al. High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany. Clin Res Cardiol. 2023 Nov;112(11):1639–1649.
   PubMed Web of Science ®Google Scholar
• Karlson BW, Wiklund O, Palmer MK, et al. Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. Eur Heart J Cardiovasc Pharmacother. 2016 Oct;2(4):212–217.
   PubMed Web of Science ®Google Scholar
• Warden BA, Cardiology BA, Purnell JQ, et al. Real-world utilization of bempedoic acid in an academic preventive cardiology practice. J Clin Lipidol. 2022 Jan;16(1):94–103.
   PubMed Web of Science ®Google Scholar
• Descamps O, Tomassini JE, Lin J, et al. Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients. Atherosclerosis. 2015 Jun;240(2):482–489.
   PubMed Web of Science ®Google Scholar
• Ray KK, Bruckert E, Peronne-Filardi P, et al. Long-term persistence with evolocumab treatment and sustained reductions in LDL-cholesterol levels over 30 months: final results from the European observational HEYMANS study. Atherosclerosis. 2023 Feb;366:14–21. doi: 10.1016/j.atherosclerosis.2023.01.002
   PubMed Web of Science ®Google Scholar
• Taylor BA, Thompson PD. Statins and their effect on PCSK9-impact and clinical relevance. Curr Atheroscler Rep. 2016 Aug;18(8):46. doi: 10.1007/s11883-016-0604-3
   PubMed Web of Science ®Google Scholar
• Oleaga C, Shapiro MD, Hay J, et al. Hepatic sensing loop regulates PCSK9 secretion in response to inhibitory antibodies. J Am Coll Cardiol. 2021 Oct 5;78(14):1437–1449. doi: 10.1016/j.jacc.2021.07.056
   PubMed Web of Science ®Google Scholar
• Xia XD, Peng ZS, Gu HM, et al. Regulation of PCSK9 expression and function: mechanisms and therapeutic implications. Front Cardiovasc Med. 2021;8:764038. doi: 10.3389/fcvm.2021.764038
   PubMed Web of Science ®Google Scholar
• Wright RS, Koenig W, Landmesser U, et al. Safety and tolerability of inclisiran for treatment of hypercholesterolemia in 7 clinical trials. J Am Coll Cardiol. 2023 Dec 12;82(24):2251–2261. doi: 10.1016/j.jacc.2023.10.007
   PubMed Web of Science ®Google Scholar
• Landmesser U, Haghikia A, Leiter LA, et al. Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1. Cardiovasc Res. 2021 Jan 1;117(1):284–291. doi: 10.1093/cvr/cvaa077
   PubMed Web of Science ®Google Scholar
• Ruscica M, Tokgozoglu L, Corsini A, et al. PCSK9 inhibition and inflammation: a narrative review. Atherosclerosis. 2019 Sep;288:146–155. doi: 10.1016/j.atherosclerosis.2019.07.015
   PubMed Web of Science ®Google Scholar
• Ray KK, Raal FJ, Kallend DG, et al. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. 2023 Jan 7;44(2):129–138. doi: 10.1093/eurheartj/ehac594
   PubMed Web of Science ®Google Scholar
• Bao X, Liang Y, Chang H, et al. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside. Signal Transduct Target Ther. 2024 Jan 8;9(1):13. doi: 10.1038/s41392-023-01690-3
   PubMed Web of Science ®Google Scholar